Latest Intercell Stories
Reportbuyer.com just published a new market research report:
Statens Serum Institut and Aeras today announced the initiation of the first Phase I clinical trial of a new candidate TB vaccine designed to protect people latently infected with TB from developing active TB disease.
VIENNA, May 10, 2011 /PRNewswire/ -- Today, the biotech-vaccine company Intercell AG (VSE: ICLL) announced its financial results for Q1 and presented an update on the Company's development programs. Financial Results Year-on-year revenue growth of 19.7% driven by strong IXIAROÂ®/JESPECTÂ® sales revenues Restructuring process progressing successfully - operating loss reduced by 33.1%Higher sales and reduced spending lead to reduced net loss of EUR 11.3mCash position of EUR 87.7m at...
VIENNA, May 5, 2011 /PRNewswire/ -- Today Intercell AG (VSE: ICLL) announced that the company's Supervisory Board has appointed Thomas Lingelbach as new Chief Executive Officer (CEO) for Intercell, effective May 10, 2011.
WHITEHOUSE STATION, N.J., and VIENNA, April 11, 2011 /PRNewswire/ -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Intercell AG (VSE: ICLL) today announced that following a pre-specified interim analysis from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus (S.
VIENNA, April 1, 2011 /PRNewswire/ -- Today Intercell AG (VSE: ICLL) announced that it has agreed with Novartis to advance Intercell's investigational Pseudomonas aeruginosa vaccine into a confirmatory clinical efficacy trial in ventilated ICU (Intensive Care Unit) patients.
VIENNA, March 1, 2011 /PRNewswire/ -- Today Intercell AG (VSE: ICLL) announced its financial results for Q4 and the preliminary results for the full financial year 2010 and presented an update on the Company's development programs. Increase in IXIAROÂ®/JESPECTÂ® sales by approximately 66% to EUR 12.8m for the full year 2010, due to increased sales in key travel markets and to U.S.
VIENNA, Feb. 22, 2011 /PRNewswire/ -- Intercell AG (VSE: ICLL) today announced the offering of EUR 30.8m of Senior Unsecured Convertible Notes (the "Notes").
- Forsooth! indeed! originally a parenthetical phrase used in repeating the words of another with more or less contempt or disdain.